Drug intelligence / Profile preview

menaquinone

Development stage
Phase 4
Lead developer
Gnosis
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Subcutaneous
01

Overview

Menaquinone is the generic name for a group of compounds collectively known as vitamin K2. It is one of the three main types of vitamin K, alongside phylloquinone (vitamin K1) and menadione (vitamin K3). Menaquinones are characterized by their unsaturated isoprenyl side chains, with subtypes designated as MK-n based on the number of isoprenyl units. The most studied forms include MK-4, MK-7, and MK-9[3][4][5]. Menaquinones are produced by bacteria in the human gut and found in animal-based foods and fermented products such as natto[3][4][6]. Mechanistically, menaquinones act as cofactors for gamma-glutamyl carboxylase enzymes that activate vitamin K-dependent proteins involved in blood clotting (e.g., prothrombin) and bone metabolism (e.g., osteocalcin)[3][5]. They also play roles in preventing vascular calcification via activation of matrix Gla protein[5]. Clinical evidence supports their use for improving bone strength/reducing fracture risk in osteoporosis; they may also benefit cardiovascular health by reducing arterial calcification[1][5][6]. Additional research suggests potential benefits for diabetes management, peripheral neuropathy, cancer suppression via cell-cycle arrest/apoptosis pathways, and possibly neuroprotection[5].

Other names
vitamin K2MKmenaquinones (MK-4 through MK-13)menatetrenone (MK-4)menaquinone-7 (MK-7)vitamin K~2~
02

Targets

GGCX (Vitamin K-dependent gamma-glutamyl carboxylase)

Beyond the preview

Go deeper on menaquinone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on menaquinone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call